There are currently 77 clinical trials in Huntsville, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including Heart Center Research, LLC, Clearview Cancer Institute, Pfizer Investigational Site and Medical Affiliated Research Center Inc. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)
NCT05781750
Recruiting
The purpose of this study is to assess the efficacy and safety of zetomipzomib (30 mg or 60 mg) compared with placebo in achieving renal response after 52 weeks of treatment in patients with active lupus nephritis (LN).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Nephrology Consultants, LLC, Huntsville, Alabama
Conditions: Lupus Nephritis
Register for Updates
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054
Recruiting
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Clearview Cancer Institute, Huntsville, Alabama
Conditions: Breast Neoplasms
Register for Updates
A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis
NCT05587309
Recruiting
The objective of the Healing Phase of the study is to evaluate the safety and efficacy of up to 8 weeks of once daily oral administration of BLI5100 versus a PPI control in healing EE. The objective of the Maintenance Phase of the study is to evaluate the safety and efficacy of 24 weeks of once daily oral administration of BLI5100 (low or high dose) versus a PPI control in the maintenance of healed EE.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
05/14/2024
Locations: Research Site 24, Huntsville, Alabama
Conditions: Erosive Esophagitis
Register for Updates
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease
NCT05312879
Recruiting
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Gender:
All
Ages:
Between 10 years and 65 years
Trial Updated:
05/14/2024
Locations: Nephrology Consultants, LLC, Huntsville, Alabama
Conditions: Proteinuric Kidney Disease
Register for Updates
To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
NCT04894591
Recruiting
To assess the effectiveness and safety of Zepzelca in adult participants with extensive stage small cell lung cancer (SCLC) in real-world clinical practice.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Clearview Cancer Institute, Huntsville, Alabama
Conditions: Extensive-stage Small-cell Lung Cancer
Register for Updates
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
NCT05832151
Recruiting
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients. The main questions it aims to answer are: To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with diabetic gastroparesis compared to a placebo To evaluate the safety and tolerability of CIN-102 when given to patients with diabetic gastroparesis compared to a placebo Participants wil... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Clinical Research Associates, LLC, Huntsville, Alabama
Conditions: Diabetic Gastroparesis
Register for Updates
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT04822181
Recruiting
Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance. Participants will need to inject themselves with medicine under the skin. Participants will need to do this once a week. The study will last for about 5 years. Participants will have up to 21 clinic visits a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: North AL Health Res, LLC, Huntsville, Alabama
Conditions: Non-alcoholic Steatohepatitis
Register for Updates
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)
NCT04609878
Recruiting
This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
05/10/2024
Locations: Research Site, Huntsville, Alabama
Conditions: Asthma
Register for Updates
Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery
NCT06021457
Recruiting
The purpose of this study is to evaluate the effect of RBT-1 on reducing the risk of post-operative complications in subjects undergoing cardiac surgery on cardiopulmonary bypass (CPB). A sub-study will also be conducted to evaluate the pharmacokinetic (PK) profile of a single administration of RBT-1 by means of a popPK approach in subjects scheduled to undergo cardiac surgery.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2024
Locations: Research Site, Huntsville, Alabama
Conditions: Post-Operative Complications in Cardiac Surgery
Register for Updates
A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
NCT06173570
Recruiting
The primary purpose of this study is to measure the effect of different daily doses of AZD0780 on Low-Density Lipoprotein (LDL-C) levels compared with placebo in participants with dyslipidemia. The effect of AZD0780 versus placebo on other lipid parameters and inflammatory markers is also investigated. The concentration of AZD0780 in blood at specific timepoints is measured, and the safety and tolerability of AZD0780 will be evaluated. There is a follow-up after end of treatment, but expanded ac... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/09/2024
Locations: Research Site, Huntsville, Alabama
Conditions: Dyslipidemia
Register for Updates
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
NCT06272487
Recruiting
The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Clinical Trial Site, Huntsville, Alabama
Conditions: High Cardiovascular Risk, Hypertension
Register for Updates
Shockwave C2+ 2Hz Coronary IVL Catheter in Calcified Coronary Arteries (Disrupt CAD DUO)
NCT05966662
Recruiting
This investigational device exemption (IDE) study is to assess the safety and effectiveness of the Shockwave Coronary Intravascular Lithotripsy (IVL) System with the Shockwave C2+ 2Hz Coronary IVL Catheter to treat de novo, calcified, stenotic, coronary lesions prior to stenting.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Heart Center Research, Huntsville, Alabama
Conditions: Coronary Artery Disease, Myocardial Infarction
Register for Updates